The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
4th Feb 20217:00 amRNSCORRECTION: MaxCyte Announces £40m Subscription
3rd Feb 20214:36 pmRNSMaxCyte Announces £40 million Subscription
3rd Feb 20214:35 pmRNSAppointment of Joint Corporate Broker
21st Jan 20212:49 pmRNSIncrease to Block Listing
20th Jan 20217:00 amRNSTrading Update
11th Jan 20217:00 amRNSMyeloid Therapeutics Clinical & Commercial License
23rd Dec 20207:00 amRNSTrading Update
9th Nov 20201:00 pmRNSCARMA Cell Therapies at SITC 2020
9th Nov 20207:00 amRNSPresentations at Upcoming Virtual IR Conferences
2nd Nov 20203:52 pmRNSResult of AGM
22nd Oct 20206:22 pmRNSDisclosure of Remuneration for Non-Audit Services
14th Oct 20207:00 amRNSNotification of AGM and Audit Declaration
13th Oct 20207:00 amRNSMaxCyte announces leadership appointments
1st Oct 20207:00 amRNSDirector/PDMR Shareholding
21st Sep 20207:00 amRNSResults for the Six Months ended 30 June 2020
10th Sep 20201:42 pmRNSGrant of options
10th Sep 20207:00 amRNSHC Wainright & Co Virtual Conference Presentation
9th Sep 20207:00 amRNSAppointment of Amanda L. Murphy as CFO
2nd Sep 20202:57 pmRNSHolding(s) in Company
2nd Sep 20207:00 amRNSNotice of Half Year Results
18th Aug 20207:00 amRNSExpansion of CARMA’s Phase I Trial of MCY-M11
14th Aug 20207:00 amRNSHolding(s) in Company
16th Jul 20206:04 pmRNSDirector Dealings and Issue of Equity
15th Jul 20207:00 amRNSTrading Update
8th Jul 20207:00 amRNSAPEIRON Biologics Clinical and Commercial License
1st Jul 20207:00 amRNSBlock Listing Return & TVR
2nd Jun 20205:54 pmRNSHolding(s) in Company
28th May 20203:34 pmRNSHolding(s) in Company
26th May 20205:49 pmRNSHolding(s) in Company
26th May 20204:22 pmRNSHolding(s) in Company
26th May 20203:45 pmRNSHoldings in Company
21st May 20201:50 pmRNSResult of Special Meeting and Issue of Equity
14th May 20207:00 amRNSPoster Presentation on MCY-M11 at ASCO 2020
7th May 20207:00 amRNSLicense Agreement with Caribou Biosciences
1st May 20207:00 amRNSResult of Offering
30th Apr 20205:39 pmRNSProposed Offering to raise up to £25.1 million
21st Apr 20207:00 amRNSFinal Results for Year Ended 31 December 2019
9th Apr 20207:00 amRNSBusiness Update Related to COVID-19 Pandemic
24th Mar 20207:00 amRNSLicense Agreement with Allogene Therapeutics
21st Feb 20207:00 amRNSConsolidation of Trading Lines
20th Feb 20206:18 pmRNSAIM Block Admission Return / Total Voting Rights
5th Feb 20207:00 amRNSMaxCyte to Present at BIO CEO & Investor Conf
24th Jan 20204:31 pmRNSGrant Of Options
22nd Jan 20205:15 pmRNSHolding(s) in Company
22nd Jan 20205:11 pmRNSHolding(s) in Company
22nd Jan 20205:08 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSTrading Update
19th Dec 20197:00 amRNSNew Executive Vice President and Trial Update
16th Dec 20195:25 pmRNSDirector/PCA transaction initial notification
4th Dec 20197:00 amRNSAgreement with KSQ Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.